Loading clinical trials...
Loading clinical trials...
This trial is conducted in Europe. The aim of this trial is to demonstrate bio-equivalence between the marketed activated recombinant human factor VII (NovoSeven®) (CP-rFVIIa) and a new formulation st...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novo Nordisk A/S
NCT02137850 · Congenital Bleeding Disorder, Haemophilia A
NCT02141074 · Congenital Bleeding Disorder, Haemophilia B
NCT01561391 · Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and more
NCT03075670 · Congenital Bleeding Disorder, Haemophilia B
NCT03528551 · Congenital Bleeding Disorder, Haemophilia A
Novo Nordisk Investigational Site
Paris
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions